In addition, emerging evidence suggests that dual GLP-1 and gastric inhibitory polypeptide (GIP) receptor (GIPR) agonists (e.g., tirzepatide), dual GLP-1 and glucagon receptor agonists (e.g., cotadutide), or triple GLP-1/GIP/glucagon receptor agonists (e.g., HM15211) may be more promising than each therapy alone for alleviating MASH and liver fibrosis, but further testing is needed [148]. This evidence concerns the gene GCGR and metabolic dysfunction-associated steatohepatitis.